Bionomics has begun the Phase 2 PREVAIL study of BNC210 for the Acute Treatment of Social Anxiety Disorder (SAD).
Bionomics Limited is pleased to announce that it has initiated its Phase 2 clinical trial (the PREVAIL Study) to evaluate BNC210 for the acute treatment of Social Anxiety Disorder (SAD), with topline ...